NCT06465550View on ClinicalTrials.gov

A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
β-thalassemia
Interventions
GENETIC

BD211

Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.

Trial Locations (3)

200025

RECRUITING

Shanghai Ruijin Hospital, Shanghai Jiaotong University, Shanghai

510120

RECRUITING

Sun Yat-sen Memorial Hospital, Guangzhou

530021

RECRUITING

The First Affiliated Hospital of Guangxi Medical University, Nanning

All Listed Sponsors
lead

Shanghai BDgene Co., Ltd.

INDUSTRY